2023
Watchman device migration and embolization: A report from the NCDR LAAO Registry
Friedman D, Freeman J, Zimmerman S, Tan Z, Pereira L, Faridi K, Curtis J. Watchman device migration and embolization: A report from the NCDR LAAO Registry. Journal Of Cardiovascular Electrophysiology 2023, 34: 1192-1195. PMID: 37078339, PMCID: PMC10290479, DOI: 10.1111/jce.15909.Peer-Reviewed Original ResearchConceptsWATCHMAN procedureSurgical retrievalDevice migrationMortality rateAtrial appendage closure deviceHospital mortality rateAnnual procedure volumeCardiac surgeryHospital eventsPostdischarge eventsOstial sizeDevice embolizationTaller patientsRetrospective analysisClosure deviceLAA ostiumPatientsProcedure volumeHigh mortalitySurgerySubstantial proportionEmbolizationRegistryGreater body massBody mass
2022
Acute Ischemic Stroke, Depressed Left Ventricular Ejection Fraction, and Sinus Rhythm: Prevalence and Practice Patterns
Baker AD, Schwamm LH, Sanborn DY, Furie K, Stretz C, Mac Grory B, Yaghi S, Kleindorfer D, Sucharew H, Mackey J, Walsh K, Flaherty M, Kissela B, Alwell K, Khoury J, Khatri P, Adeoye O, Ferioli S, Woo D, Martini S, La Rosa F, Demel SL, Madsen T, Star M, Coleman E, Slavin S, Jasne A, Mistry EA, Haverbusch M, Merkler AE, Kamel H, Schindler J, Sansing LH, Faridi KF, Sugeng L, Sheth KN, Sharma R. Acute Ischemic Stroke, Depressed Left Ventricular Ejection Fraction, and Sinus Rhythm: Prevalence and Practice Patterns. Stroke 2022, 53: 1883-1891. PMID: 35086361, PMCID: PMC10214981, DOI: 10.1161/strokeaha.121.036706.Peer-Reviewed Original ResearchConceptsLeft ventricular ejection fractionAcute ischemic strokeDepressed left ventricular ejection fractionVentricular ejection fractionSinus rhythmIschemic strokeEjection fractionPooled prevalenceHealth Stroke Severity ScaleSecondary stroke prevention strategiesMultivariable logistic regression modelAntithrombotic treatment regimensHospital-based cohortRetrospective cohort studySecondary stroke preventionStroke prevention strategiesMulti-center cohortStroke Severity ScaleLogistic regression modelsEchocardiographic characteristicsHospitalization dischargeAntiplatelet therapyStroke preventionCardiac thrombusCohort studyDays at Home After Transcatheter vs Surgical Aortic Valve Replacement in Intermediate-Risk Patients
Chung M, Faridi KF, Kazi DS, Almarzooq ZI, Song Y, Baron SJ, Yeh RW. Days at Home After Transcatheter vs Surgical Aortic Valve Replacement in Intermediate-Risk Patients. JAMA Cardiology 2022, 7: 110-112. PMID: 34668923, PMCID: PMC8529525, DOI: 10.1001/jamacardio.2021.4036.Peer-Reviewed Original Research
2020
Inpatient Transthoracic Echocardiography during the COVID-19 Pandemic: Evaluating a New Triage Process
Hennessey KC, Shah N, Soufer A, Wang Y, Agarwal V, McNamara RL, Crandall I, Balan S, Pereira J, Kim Y, Hur DJ, Velazquez EJ, Sugeng L, Faridi KF. Inpatient Transthoracic Echocardiography during the COVID-19 Pandemic: Evaluating a New Triage Process. Journal Of The American Society Of Echocardiography 2020, 33: 1418-1419. PMID: 32888760, PMCID: PMC7392041, DOI: 10.1016/j.echo.2020.07.018.Peer-Reviewed Original ResearchPhysician and Hospital Utilization of P2Y12 Inhibitors in ST-Segment–Elevation Myocardial Infarction in the United States
Faridi KF, Garratt KN, Kennedy KF, Maddox TM, Secemsky EA, Butala NM, Yeh RW. Physician and Hospital Utilization of P2Y12 Inhibitors in ST-Segment–Elevation Myocardial Infarction in the United States. Circulation Cardiovascular Quality And Outcomes 2020, 13: e006275. PMID: 32156164, DOI: 10.1161/circoutcomes.119.006275.Peer-Reviewed Original ResearchMeSH KeywordsAgedCardiologistsCardiology Service, HospitalClopidogrelDrug UtilizationFemaleHemorrhageHumansMaleMiddle AgedPatient DischargePercutaneous Coronary InterventionPlatelet Aggregation InhibitorsPractice Patterns, Physicians'Prasugrel HydrochloridePurinergic P2Y Receptor AntagonistsReceptors, Purinergic P2Y12RegistriesRetrospective StudiesRisk AssessmentRisk FactorsST Elevation Myocardial InfarctionTicagrelorTime FactorsTreatment OutcomeUnited StatesConceptsST-segment elevation myocardial infarctionP2Y12 inhibitor usePotent P2Y12 inhibitorsP2Y12 inhibitorsSTEMI patientsMyocardial infarctionInhibitor useClopidogrel usePrior percutaneous coronary interventionNew P2Y12 inhibitorsSubstantial hospital variationUse of ticagrelorElevation myocardial infarctionPercutaneous coronary interventionRisk of deathStrongest clinical predictorsNational utilization ratesBackground TicagrelorHospital quartilesCoronary interventionPatient characteristicsClinical predictorsTicagrelor useHospital variationRetrospective study
2017
Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Therapy
Hess GP, Natarajan P, Faridi KF, Fievitz A, Valsdottir L, Yeh RW. Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Therapy. Circulation 2017, 136: 2210-2219. PMID: 29084735, PMCID: PMC5716860, DOI: 10.1161/circulationaha.117.028430.Peer-Reviewed Original ResearchMeSH KeywordsAdministrative Claims, HealthcareAgedAtherosclerosisCost-Benefit AnalysisDrug CostsElectronic Health RecordsEligibility DeterminationFemaleHumansHyperlipoproteinemia Type IIHypolipidemic AgentsInsurance, Health, ReimbursementInsurance, Pharmaceutical ServicesMaleMedicareMiddle AgedPCSK9 InhibitorsProcess Assessment, Health CareProprotein Convertase 9Retrospective StudiesSerine Proteinase InhibitorsTreatment OutcomeUnited StatesConceptsProprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitorsAtherosclerotic cardiovascular diseasePCSK9i prescriptionsPayer typeCardiovascular diseaseProprotein convertase subtilisin/kexin type 9 inhibitor therapyHigher low-density lipoprotein cholesterol levelsSubtilisin/kexin type 9 inhibitorsLow-density lipoprotein cholesterol levelsClinical atherosclerotic cardiovascular diseaseDrug's high costNonprimary care providersLipoprotein cholesterol levelsDescriptive cohort studyElectronic medical recordsPCSK9i therapyPrescription approvalThird-party payersStatin useClinical characteristicsStatin intoleranceCohort studyInhibitor therapyPharmacy claimsPrescription claims
2016
Angiotensin II antagonism is associated with reduced risk for gastrointestinal bleeding caused by arteriovenous malformations in patients with left ventricular assist devices
Houston BA, Schneider AL, Vaishnav J, Cromwell DM, Miller PE, Faridi KF, Shah A, Sciortino C, Whitman G, Tedford RJ, Stevens GR, Judge DP, Russell SD, Rouf R. Angiotensin II antagonism is associated with reduced risk for gastrointestinal bleeding caused by arteriovenous malformations in patients with left ventricular assist devices. The Journal Of Heart And Lung Transplantation 2016, 36: 380-385. PMID: 28169115, DOI: 10.1016/j.healun.2016.12.016.Peer-Reviewed Original ResearchConceptsLeft ventricular assist deviceGastrointestinal bleedingAngiotensin II antagonismARB therapyVascular endothelial growth factorArteriovenous malformationsVentricular assist deviceAssist deviceAngiotensin receptor blocker therapyContinuous-flow Left Ventricular Assist DevicesAssociation of ACEIReceptor blocker therapyInternational normalized ratioRegression hazard modelGastrointestinal arteriovenous malformationsJohns Hopkins HospitalLogistic regression analysisRisk of AVMAngiotensin II SignalingEndothelial growth factorBlocker therapyRenal functionAdult patientsBlood pressureCardiomyopathy etiologyTiming of First Postdischarge Follow-up and Medication Adherence After Acute Myocardial Infarction
Faridi KF, Peterson ED, McCoy LA, Thomas L, Enriquez J, Wang TY. Timing of First Postdischarge Follow-up and Medication Adherence After Acute Myocardial Infarction. JAMA Cardiology 2016, 1: 147. PMID: 27437885, DOI: 10.1001/jamacardio.2016.0001.Peer-Reviewed Original ResearchConceptsAcute myocardial infarctionMedication adherenceClinic visitsHospital dischargeMyocardial infarctionIntervention Outcomes Network RegistryPlatelet P2Y12 receptor inhibitorsAngiotensin-converting enzyme inhibitorAcute Coronary TreatmentFirst outpatient followImproved care transitionsP2Y12 receptor inhibitorsPostdischarge Follow-upAngiotensin receptor blockersSecondary prevention therapiesLong-term prognosisLow medication adherencePatient medication adherenceProportion of daysLower household incomeGuidelines hospitalsReceptor blockersAcute MIClinical characteristicsCoronary Treatment